The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Monoclonal antibody-based therapies for microbial diseases
Open accessAbstract
The monoclonal antibody (mAb) revolution that currently provides many new options for the treatment of neoplastic and inflammatory diseases has largely bypassed the field of infectious diseases. Only one mAb is licensed for use against an infectious disease, although there are many in various stages of development. This situation is peculiar given that serum therapy was one of the first effective treatments for microbial diseases and that specific antibodies have numerous antimicrobial properties. The underdevelopment and underutilization of mAb therapies for microbial diseases has various complex explanations that include the current availability of antimicrobial drugs, small markets, high costs and microbial antigenic variation. However, there are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Currently, the major hurdle for the widespread introduction of mAb therapies for microbial diseases is economic, given the high costs of immunoglobulin preparations and relatively small markets. Despite these obstacles there are numerous opportunities for mAb development against microbial diseases and the development of radioimmunotherapy provides new options for enhancing the magic bullet. Hence, there is cautious optimism that the years ahead will see more mAbs in clinical use against microbial diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 2×
“For example, alterations in Fc region glycosylation can increase antibody-dependent cell-mediated cytotoxicity (ADCC) [101].”
Passive immunity in prevention and treatment of infectious diseases
Keller, M. A., & Stiehm, E. R. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.4.602 · Cited by 388
Antibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Serum therapy revisited: animal models of infection and development of passive antibody therapy
Casadevall, A., & Scharff, M. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1695 · Cited by 251
Self-citationRagle, B. E., & Bubeck Wardenburg, J. (2009) · Infection and Immunity · doi:10.1128/iai.00115-09 · Cited by 202
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum
Nosanchuk, J. D., Steenbergen, J. N., Shi, L., Deepe, G. S., & Casadevall, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19361 · Cited by 178
Self-citationMonoclonal antibodies in Pediatrics: use in prevention and treatment
Martin-Mateos, M. A. (2007) · Allergologia et Immunopathologia · doi:10.1157/13108225 · Cited by 20
Cited by
Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance
Ghosh, C., Sarkar, P., Issa, R., & Haldar, J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.12.010 · Cited by 661
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0426-7 · Cited by 332
Metal-Based Nanoparticles for the Treatment of Infectious Diseases
Aderibigbe, B. (2017) · Molecules · doi:10.3390/molecules22081370 · Cited by 269
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Metadata
- Authors
- Saylor, C., Dadachova, E., & Casadevall, A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 27
- Pages
- G38-G46
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2156687094
- Cited by
- 172
- References
- 9
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monoclonal antibody-based therapies for microbial diseases. https://app.cochat.ai/papers/10.1016/j.vaccine.2009.09.105
- The paper
- Saylor, C., Dadachova, E., & Casadevall, A. (2009). Monoclonal antibody-based therapies for microbial diseases. Vaccine. https://doi.org/10.1016/j.vaccine.2009.09.105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.